SCIENTIFIC HUB

Follow the evidence.

SCIENTIFIC LITERATURE · MED

Continuous subcutaneous foscarbidopa/foslevodopa infusion as a therapeutic option in spinocerebellar ataxia type 8 presenting with early-onset parkinsonism.

Clin Park Relat Disord · 2026-08-27

DOI: 10.1016/j.prdoa.2026.100496PMID: 42725084

Open accessJournal Article; Case Reports; case-reportOriginal source ↗

Research overview

The text below is the source article’s original abstract under a verified reuse license. cc by

In response to a case report on a patient with spinocerebellar ataxia type 8, presenting with early-onset parkinsonism and treated with deep brain stimulation, we report an analogous case, who responded optimally to continuous subcutaneous foscarbidopa/foslevodopa infusion.

Scientific assessment

01

Research question

Assess the question within the original study’s scope.

02

Methods & sample

Check the source article for study design and sample details.

03

Key findings

An editorially approved findings summary is not yet published for this record.

04

Limitations

Generalizability, bias and clinical meaning require separate assessment.

Methods, samples and clinical conclusions are not inferred from bibliographic metadata.